# N-Acetyl Semax Amidate: Variants and Analogs in Research

> N-Acetyl Semax Amidate is the most proteolytically stable Semax analog in the literature. This page documents the structural differences, stability data, and research context for Semax, N-Acetyl Semax, and N-Acetyl Semax Amidate.

## N-Acetyl Semax Amidate: Variants and Analogs in Research

N-Acetyl Semax Amidate is the most proteolytically stable form of the Semax compound family in the published research literature. [17][18] The three main analogs share the core heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro) but differ in N-terminal and C-terminal modifications that substantially affect enzymatic degradation rates.

Two enzyme classes are primarily responsible for Semax catabolism: aminopeptidases (cleave from the N-terminus) and carboxypeptidases (cleave from the C-terminus). Modifications that block either terminus slow the corresponding enzyme class. [17][18]

## Semax vs N-Acetyl Semax vs N-Acetyl Semax Amidate

**Semax (parent compound).** The unmodified heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. Plasma half-life approximately 2-5 minutes under typical serum enzyme activity. Downstream neurotrophin signaling extends effects substantially beyond clearance. [9]

**N-Acetyl Semax.** Acetyl group added to the N-terminal methionine. Shevchenko et al. (2013) demonstrated that N-acetylation reduces N-terminal aminopeptidase susceptibility. [18] The C-terminus remains subject to carboxypeptidase activity — a partial stability improvement.

**N-Acetyl Semax Amidate.** Both N-terminal acetylation and C-terminal amidation (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2). C-terminal amidation blocks carboxypeptidase cleavage of the terminal proline. Combining both modifications produces a peptide resistant to both major degradation pathways. [17][18]

## Proteolytic stability data

Shevchenko et al. (2013, Doklady Biological Sciences) examined carboxypeptidase-mediated proteolysis of Semax analogs with different N-terminal amino acids, demonstrating that N-terminal modifications alter degradation rates in a predictable manner. [17]

The second Shevchenko et al. (2013) study characterized the stability of N-acetylated Semax in biological media — examining leucyl aminopeptidase and microsomal enzyme pathways. [18]

Neither study characterized N-Acetyl Semax Amidate's stability directly; the amidated form's predicted stability advantage is extrapolated from the cumulative effect of both modifications.

## Research context for Semax analog selection

The existing Semax literature — BDNF upregulation, ischemia neuroprotection, behavioral studies — was conducted primarily with the parent compound. [1][2][3][4][5][6][7][8] The N-acetyl and amidated analogs have been characterized structurally and for proteolytic stability [17][18] but have not been the primary compound in published efficacy studies of comparable scope.

## References

[1] Dolotov OV, et al. Semax increases BDNF in rat basal forebrain. Journal of Neurochemistry. 2006. — https://pubmed.ncbi.nlm.nih.gov/16635254/
[2] Dolotov OV, et al. Semax regulates BDNF and trkB in rat hippocampus. Brain Research. 2006. — https://pubmed.ncbi.nlm.nih.gov/16996037/
[9] Shevchenko KV, et al. Kinetics of Semax penetration into rat brain. 2006. — https://pubmed.ncbi.nlm.nih.gov/16523722/
[17] Shevchenko KV, et al. Proteolysis of Semax analogues by carboxypeptidases. Doklady Biological Sciences. 2013. — https://pubmed.ncbi.nlm.nih.gov/23821053/
[18] Shevchenko KV, et al. Stability of Semax acetyl to proteolysis in biological media. 2013. — https://pubmed.ncbi.nlm.nih.gov/23652441/

---

A kiln-fired digest of the peer-reviewed Semax record — heptapeptide research indexed from the literature, no clinic behind the shelf.